|
Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
|
26 April 2011 |
|
Bayer's Rivaroxaban Submitted for Approval in Japan
|
15 April 2011 |
|
Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
|
11 April 2011 |
|
OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics
|
13 March 2011 |
|
Bayer extends support to fight Chagas disease
|
04 March 2011 |
|
Breaking the Taboo Associated with Hemorrhoidal Disease
|
02 March 2011 |
|
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
|
24 February 2011 |
|
FDA Grants Orphan Drug Designation to Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
|
09 February 2011 |
|
Bayer and Zydus Cadila sign Joint Venture Agreement
|
30 January 2011 |
|
Bayer and Regeneron start MYRROR Phase III Trial
|
19 January 2011 |
|
New Bayer U.S. Innovation Center starts its operations
|
12 January 2011 |
|
Bayer: 35 million Euros for the expansion of the development of biologicals
|
13 December 2010 |
|
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
|
23 November 2010 |
|
Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
|
15 November 2010 |
|
Bayer raises its brand profile
|
08 November 2010 |
|
Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
|
02 November 2010 |
|
Bayer lifts sales and earnings again
|
29 October 2010 |
|
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
|
18 October 2010 |
|
Bayer's Xarelto® Recognised with 2010 International Prix Galien Award
|
07 October 2010 |
|
Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome
|
01 September 2010 |